Gyre Therapeutics, Inc. (GYRE) Reports Q3 EPS of $0.01

Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 EPS of $0.01. Revenue for the quarter came in at $25.49 million, versus $0 reported last year.

For earnings history and earnings-related data on Gyre Therapeutics, Inc. (GYRE) click here.

You May Also Be Interested In

• Costco (COST) Tops Q4 EPS by 20c
• MGM Resorts rejects discussing making bid for People - WSJ
• Ancora pressures H.B. Fuller board to explore strategic alternatives